GSK Will Answer FDA “Complete Response” Letter For Cervarix In Second Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee review of the human papilloma virus vaccine expected, CEO Garnier says during year-end earnings call.
You may also be interested in...
GSK’s Responds To FDA On Cervarix, Will Augment BLA With More Efficacy Data
Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.
GSK’s Responds To FDA On Cervarix, Will Augment BLA With More Efficacy Data
Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.
Merck Receives FDA “Complete Response” On Gardasil For Women 27-45
Firm also receives complete response to its sBLA for cross-protection.